| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/PBC.26028 |
| P698 | PubMed publication ID | 27100618 |
| P50 | author | Meinolf Suttorp | Q90738365 |
| P2093 | author name string | Robert J Arceci | |
| Paul Lee | |||
| Donald Zimmerman | |||
| Nobuko Hijiya | |||
| Jill Samis | |||
| P2860 | cites work | Does imatinib mesylate therapy cause growth hormone deficiency? | Q43299932 |
| Effects and outcome of a policy of intermittent imatinib treatment in elderly patients with chronic myeloid leukemia | Q44680313 | ||
| Imatinib mesylate may improve fasting blood glucose in diabetic Ph+ chronic myelogenous leukemia patients responsive to treatment | Q45150123 | ||
| How I treat leukemia during pregnancy | Q45286228 | ||
| Pregnancies in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitor | Q45895525 | ||
| Imatinib mesylate causes growth plate closure in vivo. | Q45922577 | ||
| Decreased bone turnover despite persistent secondary hyperparathyroidism during prolonged treatment with imatinib | Q46143615 | ||
| Growth deceleration in a girl treated with imatinib | Q46158019 | ||
| Long-term imatinib therapy promotes bone formation in CML patients | Q46278690 | ||
| Imatinib and regression of type 2 diabetes | Q46367777 | ||
| Low bone density and decreased inhibin-B/FSH ratio in a boy treated with imatinib during puberty | Q46487866 | ||
| Inhibition of c-fms by imatinib: expanding the spectrum of treatment. | Q46510966 | ||
| Imatinib induces hypothyroidism in patients receiving levothyroxine | Q46731246 | ||
| Pregnancy among patients with chronic myeloid leukemia treated with imatinib | Q46919065 | ||
| Significant weight gain in patients with chronic myeloid leukemia after imatinib therapy | Q47266191 | ||
| Tyrosine kinase inhibitors noncompetitively inhibit MCT8-mediated iodothyronine transport | Q48819442 | ||
| Managing children with chronic myeloid leukaemia (CML): recommendations for the management of CML in children and young people up to the age of 18 years. | Q51072279 | ||
| Nilotinib exacerbates diabetes mellitus by decreasing secretion of endogenous insulin. | Q51294189 | ||
| Rapid amelioration of hyperglycemia facilitated by dasatinib in a chronic myeloid leukemia patient with type 2 diabetes mellitus. | Q51350666 | ||
| Inhibition of platelet-derived growth factor receptorbeta by imatinib mesylate suppresses proliferation and alters differentiation of human mesenchymal stem cells in vitro. | Q53550364 | ||
| Food and Drug Administration drug approval summary: Sunitinib malate for the treatment of gastrointestinal stromal tumor and advanced renal cell carcinoma. | Q53577002 | ||
| Acquired growth hormone deficiency in a girl with chronic myelogenous leukemia treated with tyrosine kinase inhibitor therapy. | Q54614929 | ||
| Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets | Q55115709 | ||
| Improved tolerability by a modified intermittent treatment schedule of dasatinib for patients with chronic myeloid leukemia resistant or intolerant to imatinib | Q58023728 | ||
| Comprehensive analysis of kinase inhibitor selectivity | Q29616719 | ||
| TK inhibitor treatment disrupts growth hormone axis: clinical observations in children with CML and experimental data from a juvenile animal model | Q30635067 | ||
| Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome | Q33336718 | ||
| Height adjustment in assessing dual energy x-ray absorptiometry measurements of bone mass and density in children | Q33526749 | ||
| Tyrosine kinase inhibitors and pregnancy | Q33568481 | ||
| Risk of Neoplasia in Pediatric Patients Receiving Growth Hormone Therapy--A Report From the Pediatric Endocrine Society Drug and Therapeutics Committee | Q33570283 | ||
| Distinct impact of imatinib on growth at prepubertal and pubertal ages of children with chronic myeloid leukemia | Q34185893 | ||
| Endocrine side effects of broad-acting kinase inhibitors | Q34574985 | ||
| Clinical review: kinase inhibitors: adverse effects related to the endocrine system | Q36736494 | ||
| Tyrosine kinase inhibitors reverse type 1 diabetes in nonobese diabetic mice | Q36999931 | ||
| Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure | Q37027759 | ||
| The effects of imatinib on pregnancy outcome | Q37028624 | ||
| Hypothyroidism related to tyrosine kinase inhibitors: an emerging toxic effect of targeted therapy. | Q37427388 | ||
| Higher dose imatinib for children with de novo chronic phase chronic myelogenous leukemia: a report from the Children's Oncology Group | Q37505017 | ||
| Dysregulation of bone remodeling by imatinib mesylate. | Q37627491 | ||
| Imatinib mesylate causes growth deceleration in pediatric patients with chronic myelogenous leukemia | Q37989418 | ||
| Practical issues surrounding the explosion of tyrosine kinase inhibitors for the management of chronic myeloid leukemia | Q38225275 | ||
| Chronic myeloid leukemia in children: clinical findings, management, and unanswered questions | Q38272877 | ||
| Management of adverse events associated with tyrosine kinase inhibitors in chronic myeloid leukemia | Q38392679 | ||
| Managing pregnancy in chronic myeloid leukaemia | Q38392686 | ||
| Imatinib is effective in children with previously untreated chronic myelogenous leukemia in early chronic phase: results of the French national phase IV trial | Q38489561 | ||
| Imatinib inhibits proliferation of human mesenchymal stem cells and promotes early but not late osteoblast differentiation in vitro | Q39459161 | ||
| Growth failure in children with chronic myeloid leukemia receiving imatinib is due to disruption of GH/IGF-1 axis | Q39484798 | ||
| Prevalence of vitamin D deficiency among healthy adolescents | Q39686796 | ||
| Amelioration of diabetes by imatinib mesylate (Gleevec): role of beta-cell NF-kappaB activation and anti-apoptotic preconditioning | Q40202824 | ||
| Growth deceleration in children treated with imatinib for chronic myeloid leukaemia | Q41743824 | ||
| Effects of imatinib mesylate in osteoblastogenesis | Q42451191 | ||
| Longitudinal growth retardation in a prepuberal girl with chronic myeloid leukemia on long-term treatment with imatinib | Q42662883 | ||
| Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial | Q42851077 | ||
| Thyroid dysfunction caused by second-generation tyrosine kinase inhibitors in Philadelphia chromosome-positive chronic myeloid leukemia | Q42867411 | ||
| The tyrosine kinase inhibitor dasatinib dysregulates bone remodeling through inhibition of osteoclasts in vivo | Q43131941 | ||
| Bone metabolism, growth rate and pubertal development in children with chronic myeloid leukemia treated with imatinib during puberty | Q43156043 | ||
| Is there any relationship between imatinib mesylate medication and hypothalamic-pituitary-adrenal axis dysfunction? | Q43188557 | ||
| P433 | issue | 8 | |
| P304 | page(s) | 1332-1338 | |
| P577 | publication date | 2016-04-21 | |
| P1433 | published in | Pediatric Blood & Cancer | Q15754342 |
| P1476 | title | Recognizing Endocrinopathies Associated With Tyrosine Kinase Inhibitor Therapy in Children With Chronic Myelogenous Leukemia | |
| P478 | volume | 63 |
| Q90067699 | Evaluating the endometabolic and bone health effects of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukaemia: a systematic review protocol |
| Q56967295 | Front-line imatinib treatment in children and adolescents with chronic myeloid leukemia: results from a phase III trial |
| Q48299846 | Helping children with growth failure due to tyrosine kinase inhibitor drugs requires knowledge of the pathogenesis of the problem |
| Q92647093 | Paediatric chronic myeloid leukaemia: Is it really a different disease? |
| Q50094239 | Pharmacology and pharmacokinetics of imatinib in pediatric patients |
| Q51363096 | T-cell-rich HLA-haploidentical hematopoietic stem cell transplantation for relapsed/refractory pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia without posttransplant tyrosine kinase inhibitor therapy. |
| Q64108081 | The Bone Phenotype and Pain Response to Pamidronate in Tyrosine Kinase Inhibitor-Treated Chronic Myelogenous Leukemia |
| Q48146200 | The complexity of growth failure in children receiving tyrosine kinase inhibitor therapy for chronic myelogenous leukemia |
| Q94502757 | Vaccination With Live Attenuated Vaccines in Four Children With Chronic Myeloid Leukemia While on Imatinib Treatment |
Search more.